Standard InChI: InChI=1S/C24H27N5/c1-16-13-24-25-15-21(18(3)29(24)27-16)23-9-7-20-14-19(6-8-22(20)26-23)10-12-28-11-4-5-17(28)2/h6-9,13-15,17H,4-5,10-12H2,1-3H3/t17-/m1/s1
1.Altenbach RJ, Liu H, Banfor PN, Browman KE, Fox GB, Fryer RM, Komater VA, Krueger KM, Marsh K, Miller TR, Pan JB, Pan L, Sun M, Thiffault C, Wetter J, Zhao C, Zhou D, Esbenshade TA, Hancock AA, Cowart MD.. (2007) Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists., 50 (22):[PMID:17918921][10.1021/jm0705051]
2.Liu H, Altenbach RJ, Diaz GJ, Manelli AM, Martin RL, Miller TR, Esbenshade TA, Brioni JD, Cowart MD.. (2010) In vitro studies on a class of quinoline containing histamine H3 antagonists., 20 (11):[PMID:20457525][10.1016/j.bmcl.2010.04.045]
3.Levoin N, Labeeuw O, Calmels T, Poupardin-Olivier O, Berrebi-Bertrand I, Lecomte JM, Schwartz JC, Capet M.. (2011) Novel and highly potent histamine H3 receptor ligands. Part 1: withdrawing of hERG activity., 21 (18):[PMID:21802950][10.1016/j.bmcl.2011.07.006]
4.Berlin M, Boyce CW, Ruiz Mde L.. (2011) Histamine H3 receptor as a drug discovery target., 54 (1):[PMID:21062081][10.1021/jm100064d]